Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells

Bio-Medical Materials and Engineering

Volumn 19, Issue 4-5, 2009, Pages 271-276

  Schallmoser, Katharina ^a   Rohde, Eva ^a   Bartmann, Christina ^a   Obenauf, Anna C ^a   Reinisch, Andreas ^a   Strunk, Dirk ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

GMP compliant propagation; Multipotent mesenchymal stromal cells (MSCs); Pooled human platelet lysate (pHPL)

Indexed keywords

BONE MARROW; CELL THERAPY; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATIONS; EFFECTIVE TIME; EX-VIVO; FETAL BOVINE SERUM; GENOMIC STABILITY; GMP-COMPLIANT PROPAGATION; GOOD MANUFACTURING PRACTICES; IN-CELL; L-GLUTAMINE; LONG-TERM SAFETY; MESENCHYMAL STROMAL CELLS; PLATELET-DERIVED GROWTH FACTORS; POTENTIAL RISKS; PRIMARY CULTURE; REGENERATIVE MEDICINE; RELEASE CRITERIA; STEM CELL;

AMINO ACIDS; ANIMAL CELL CULTURE; BIOACTIVITY; BLOOD SUBSTITUTES; BODY FLUIDS; FLOWCHARTING; GENES; PEPTIDES; PLATELETS; STABILITY CRITERIA; STEM CELLS;

CELL CULTURE;

ANIMALIA; BOVINAE;

PLATELET DERIVED GROWTH FACTOR;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; HUMAN; INTERNATIONAL COOPERATION; MESENCHYMAL STEM CELL; METHODOLOGY; PHYSIOLOGY; STANDARD; TISSUE ENGINEERING;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; INTERNATIONALITY; MESENCHYMAL STEM CELLS; PLATELET-DERIVED GROWTH FACTOR; TISSUE ENGINEERING;

EID: 77049093020     PISSN: 09592989     EISSN: None     Source Type: Journal    
DOI: 10.3233/BME-2009-0591     Document Type: Article

References (51)

1. A.S. Daar and H.L. Greenwood, A proposed definition of regenerative medicine, J. Tissue Eng. Regen. Med. 1(3) (2007), 179-184.
2. M. Mimeault, R. Hauke and S.K. Batra, Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies, Clin. Pharmacol. Ther. 82(3) (2007), 252-264.
3. J. Cohnheim, Ueber Entzündung und Eiterung, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 40(1,2) (1867), 1-79.
4. A.J. Friedenstein et al., Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo, Transplantation 17(4) (1974), 331-340.
5. A.J. Friedenstein et al., Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method, Exp. Hematol. 2(2) (1974), 83-92.
6. A.I. Caplan, Mesenchymal stem cells, J. Orthop. Res. 9(5) (1991), 641-650.
7. D.J. Prockop, Marrow stromal cells as stem cells for nonhematopoietic tissues, Science 276(5309) (1997), 71-74.
8. M.F. Pittenger et al., Multilineage potential of adult human mesenchymal stem cells, Science 284(5411) (1999), 143-147.
9. M. Dominici et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy 8(4) (2006), 315-317.
10. P.K. Subbanna,Mesenchymal stem cells for treating GVHD: in-vivo fate and optimal dose, Med. Hypotheses 69(2) (2007), 469-470.
11. A.I. Caplan, Adult mesenchymal stem cells for tissue engineering versus regenerative medicine, J. Cell. Physiol. 213(2) (2007), 341-347.
12. C. Bartmann et al., Two steps to functional mesenchymal stromal cells for clinical application, Transfusion 47(8) (2007), 1426-1435.
13. T.A. Selvaggi, R.E. Walker and T.A. Fleisher, Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions, Blood 89(3) (1997), 776-779.
14. A. Mackensen et al., Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells, Cancer Immunol. Immunother. 49(3) (2000), 152-156.
15. E.M. Horwitz et al., Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone, Proc. Natl. Acad. Sci. USA 99(13) (2002), 8932-8937.
16. G.A. Tonti and F. Mannello, From bone marrow to therapeutic applications: different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera?, Int. J. Dev. Biol. 52(8) (2008), 1023-1032.
17. G. de Gaetano, Historical overview of the role of platelets in hemostasis and thrombosis, Haematologica 86(4) (2001), 349-356.
18. D. Ribatti and E. Crivellato, Giulio Bizzozero and the discovery of platelets, Leuk. Res. 31(10) (2007), 1339-1341.
19. G.L. Reed, Platelet secretion, in: Platelets, A.D. Michelson, ed., Elsevier, Worcester, MA, 2007, pp. 181-195.
20. A.T. Nurden et al., Platelets and wound healing, Front. Biosci. 13 (2008), 3532-3548.
21. S. Barrientos et al., Growth factors and cytokines in wound healing, Wound Repair Regen. 16(5) (2008), 585-601.
22. Y. Yamada et al., Autogenous injectable bone for regeneration with mesenchymal stem cells and platelet-rich plasma: tissue-engineered bone regeneration, Tissue Eng. 10(5,6) (2004), 955-964.
23. P. Borzini and L. Mazzucco, Tissue regeneration and in loco administration of platelet derivatives: clinical outcome, heterogeneous products, and heterogeneity of the effector mechanisms, Transfusion 45(11) (2005), 1759-1767.
24. E. Anitua et al., New insights into and novel applications for platelet-rich fibrin therapies, Trends Biotechnol. 24(5) (2006), 227-234.
25. E. Anitua et al., Delivering growth factors for therapeutics, Trends Pharmacol. Sci. 29(1) (2008), 37-41.
26. H. Kitoh et al., Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis - a preliminary result of three cases, Bone 35(4) (2004), 892-898.
27. F. Pieri et al., Effect of mesenchymal stem cells and platelet-rich plasma on the healing of standardized bone defects in the alveolar ridge: a comparative histomorphometric study in minipigs, J. Oral Maxillofac. Surg. 67(2) (2009), 265-272.
28. H. Hibi et al., Alveolar cleft osteoplasty using tissue-engineered osteogenic material, Int. J. Oral Maxillofac. Surg. 35(6) (2006), 551-555.
29. M.J. Martinez-Zapata et al., Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: a systematic review, Transfusion 49(1) (2009), 44-56.
30. G. Weibrich et al., Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count, J. Craniomaxillofac. Surg. 30(2) (2002), 97-102.
31. J.P. Frechette, I. Martineau and G. Gagnon, Platelet-rich plasmas: growth factor content and roles in wound healing, J. Dent. Res. 84(5) (2005), 434-439.
32. E. Anitua et al., The potential impact of the preparation rich in growth factors (PRGF) in different medical fields, Biomaterials 28(31) (2007), 4551-4560.
33. F. Giacco et al., Thrombin-activated platelets induce proliferation of human skin fibroblasts by stimulating autocrine production of insulin-like growth factor-1, FASEB J. 20(13) (2006), 2402-2404.
34. A. Kocaoemer et al., Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue, Stem Cells 25(5) (2007), 1270-1278.
35. N. Kakudo et al., Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts, Plast. Reconstr. Surg. 122(5) (2008), 1352-1360.
36. K. Bieback et al., Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow, Stem Cells 27 (2009), 2331-2341.
37. C. Doucet et al., Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications, J. Cell. Physiol. 205(2) (2005), 228-236.
38. K. Schallmoser and D. Strunk, Preparation of pooled Human Platelet Lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures, JoVE 32 (2009), doi:10.3791/1523; available at: http://www.jove.com/ index/details.stp?id=1523.
39. K. Schallmoser et al., Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells, Transfusion 47(8) (2007), 1436-1446.
40. A. Reinisch et al., Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application, Regen. Med. 2(4) (2007), 371-382.
41. K. Schallmoser et al., Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum, Tissue Eng. Part C Methods 14(3) (2008), 185-196.
42. A. Reinisch et al., Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo, Blood 113(26) (2009), 6716-6725.
43. C. Lange et al., Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine, J. Cell. Physiol. 213(1) (2007), 18-26.
44. M.E. Bernardo et al., Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute, J. Cell. Physiol. 211(1) (2007), 121-130.
45. S. Carrancio et al., Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification, Exp. Hematol. 36(8) (2008), 1014-1021.
46. E. Rohde et al., GMP-compliant propagation of human multipotent mesenchymal stromal cells, in: Pharmaceutical Manufacturing Handbook: Regulations and Quality, S.C. Gad, ed., Wiley, 2008, pp. 97-115.
47. D. Rubio et al., Spontaneous human adult stem cell transformation, Cancer Res. 65(8) (2005), 3035-3039.
48. M. Miura et al., Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation, Stem Cells 24(4) (2006), 1095-1103.
49. E.L. Spaeth et al., Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression, PLoS One 4(4) (2009), e4992.
50. P.J. Mishra, J.W. Glod and D. Banerjee, Mesenchymal stem cells: flip side of the coin, Cancer Res. 69(4) (2009), 1255-1258.
51. M. Breitbach et al., Potential risks of bone marrow cell transplantation into infarcted hearts, Blood 110(4) (2007), 1362-1369.